1 / 44

Alcohol: Research to Practice

Alcohol: Research to Practice. Gail D’Onofrio MD, MS Section of Emergency Medicine Yale University School of Medicine. Case Study.

dieter-morin
Télécharger la présentation

Alcohol: Research to Practice

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Alcohol: Research to Practice Gail D’Onofrio MD, MS Section of Emergency Medicine Yale University School of Medicine

  2. Case Study Mr. Smith is a 35 year old white male who presents with a new onset seizure this morning. He has no known past medical history, and takes no regular medications. He does not have a primary care physician

  3. Initial Management • History • Physical Exam • Laboratory tests • Diagnostic Imaging

  4. ETHANOL CNS Neuron GABA GABAA Receptor glutamate Cl- NMDA receptor NO Ca++ Ca++ Cl- VOCCL,N Glycine Receptor

  5. Alcohol Dependence 3 or more of these criteria in a 12-month period: 1. Tolerance 2. Withdrawal 3. More or longer consumption than intended 4. Cannot cut down or control alcohol use 5. A great deal of time getting, using, recovering 6. Activities given up or reduced 7. Use despite knowledge of health problem (3-7) Loss of control/preoccupation American Psychiatric Association DSM IV, 1994

  6. Alcohol-Related Seizures • Adult onset seizures occurring in the setting of chronic alcohol dependence

  7. Historical perspective • Hippocrates 400 B.C. - first description • Isbell 1955 - first experimental study • Victor and Brausch 1967 - landmark study

  8. Alcohol-Related Seizures - Withdrawal • Recurrent detoxifications and prior seizure are risk factors • Occur 24-48 hrs after abstinence or decreased intake • Often occur prior to autonomic hyperactivity • Generalized, single or a few over a short time • < 3% status epilepticus • 79% < 3 • 86% recurrent seizure within 6 hrs Victor and Brausch. Epilepsia 1967;8:1,

  9. Differential diagnosis • Structural brain lesions Stroke & traumatic brain injury. Susceptibility due to cerebral atrophy and head trauma • Toxic-metabolic disorders Alkalosis, hypomagnesemia, hypoglycemia & illicit drug use

  10. Differential diagnosis • Alcohol withdrawal – underestimated as a cause of generalized seizures • Idiopathic generalized epilepsy - poor seizure control in alcohol dependence • Sleep deprivation & medication compliance

  11. Pathogenesis • Biochemical effects of alcohol on CNS • Kindling - increased susceptibility and severity of recurrent withdrawal episodes. • Brown 1988 – no. of prior detoxifications a risk factor

  12. Diagnostic evaluation • Screening for alcohol dependence • Laboratory testing –rarely changes management. • Earnest 1988 - head CT indicated for all patients with new-onset alcohol-related seizures • Sand 2002 – EEGs on all patients

  13. Seizure Recurrence • 186 subjects with alcohol withdrawal seizures • RCT, double blinded • 2 mg of lorazepam IV • Also decreased hospital admission • D'Onofrio G et al. N Engl J Med 1999;340:915-919.

  14. Treatment of Alcohol Withdrawal

  15. Alcohol Withdrawal (DSM-IV) • Cessation or reduction in alcohol use that has been heavy/prolonged • Two or more of the following, developing in hours-days, causing distress or impairment, not due to other condition • Autonomic hyperactivity (sweating, tachycardia) • Increased hand tremor • Insomnia • Nausea or vomiting • Transient tactile, visual or auditory hallucinations or illusions • Psychomotor agitation • Anxiety • Grand mal seizures

  16. Detoxification: Inpatient versus Outpatient with mild/moderate alcohol withdrawal (RCT) OUTpt (N=87) INpt (N=77) Completing treatment (%)* 72 95 Abstinence (1 month)(%)** 66 81 No Intoxication (1 month)(%)* 76 88 Abstinence (6 months)(%) 48 46 No Intoxication (6 mo)(%) 59 51 Days of treatment (mean)* 4.5 9.2 Cost ($)* 175-388 3319-3665 No difference in Addiction Severity Scores *p<.001, **p<0.03. Hayashida et al. NEJM 1989;320:358

  17. Pharmacologic Therapies for Alcohol Withdrawal * Drug has a Food and Drug Administration-approved indication for this use in the US O’Connor P, et al. NEJM 1998;338;9;592-602

  18. Pharmacological Therapies for Alcohol Withdrawal O’Connor P, et al. NEJM 1998;338;9;592-602

  19. CIWA-Ar CIWA-Ar denotes: Clinical Institute Withdrawal Assessment for Alcohol, revised. The scale assesses 10 domains (nausea or vomiting; anxiety; tremor; sweating; auditory, visual, and tactile disturbances; headache; agitation; and clouding of sensorium) and assigns 0 to 7 points for each item except for the last item, which is assigned 0 to 4 points, with a total possible score of 67. This scale has been validated as a measure to assess the severity of alcohol withdrawal. Higher scores indicate a higher risk of complications; patients receiving scores of 8 or more should be treated.* *Mayo-Smith MF. JAMA 1997;278:144-51.

  20. Symptom-triggered Therapy • 101 adults with no past seizures hospitalized for alcohol withdrawal • Placebo or Chlordiazepoxide 50 mg qid X4 then 25 mg qid X8 (double-blind) • ALL: Chlordiazepoxide 25-100 mg q 1 hour as needed (objective scale: CIWA-Ar) Saitz R et al JAMA 1994;272:519-23

  21. Decreased Duration of Treatment Saitz R et al JAMA 1994;272:519-23

  22. ASAM Practice GuidelinesTreatment approaches • Monitor q 4-8 hrs until symptoms improved • Symptom-triggered (q 1 when CIWA>8) • Chlordiazepoxide 50-100 mg • Diazepam 10-20 mg • Lorazepam 2-4 mg • Fixed schedule (q 6 for 4/8 doses + PRN) • Chlordiazepoxide 50 mg/25 mg • Diazepam 10 mg/5 mg • Lorazepam 2 mg/1 mg Mayo-Smith and ASAM working group JAMA 1997;278:144-51 Saitz and O’Malley Med Clin N A 1997;81:881-907

  23. Treatment of Alcohol Dependence Detoxification is NOT treatment • Behavioral Counseling • Motivational • Cognitive-behavioral (Cue exposure, contingency management, coping skills • 12 step • Psychotherapy • Pharmacotherapy

  24. Treatment Does Work • 2/3rds of patients (1-year) reduce: • Consequences of alcohol consumption (injury job loss) • Amount of consumption by > 50% • 1/3 of patients treated are either abstinent or drink moderately without consequences Miller WR, Walters ST, Bennett ME. How effective is alcoholism treatment in the US? J Stud Alcohol 2001;62:211-20

  25. Success Rates for Addictive Disorders * Follow-up 6 mo. Data are median (range) O, Brien C; McLellan A. Lancet 1996;347;237-40

  26. Compliance and Relapse in Selected Chronic Medical Disorders *Retreatment within 12 mo by physician at emergency room or hospital; +Requiring medication O, Brien C; McLellan A. Lancet 1996;347;237-40

  27. Self Help/Mutual Help

  28. Alcoholics Anonymous (AA) • Provides support at no charge • Veteran study shows higher frequency of abstinence at 12 months than those programs with CBT (26% vs 19%) • Participation in AA associated with higher rates of abstinence 7 months after inpt tx compared with no participation. Quimette PC, et al. Twelve-step and cognitive-behavioral treatment for substance abuse: a comparison of treatment effectiveness. J Consult Clin Psychol 1997;65:230-40. Montgomery HA et al. Does AA involvement predict treatment outcomes? J Subst Abuse Treat 1995;12:241-6.

  29. AA • We admitted we were powerless over alcohol - that our lives had become unmanageable. • 2. Came to believe that a Power greater than ourselves could restore us to sanity. • 3. Made a decision to turn our will and our lives over to the care of God as we understood Him. • 4. Made a searching and fearless moral inventory of ourselves. • 5. Admitted to God, to ourselves and to another human being the exact nature of our wrongs. • 6. Were entirely ready to have God remove all these defects of character.

  30. AA (continued) 7. Humbly asked Him to remove our shortcomings. 8. Made a list of all persons we had harmed, and became willing to make amends to them all. 9. Made direct amends to such people wherever possible, except when to do so would injure them or others. 10. Continued to take personal inventory, + when we were wrong promptly admitted it. 11. Sought through prayer and meditation to improve our conscious contact with God as we understood Him, praying only for knowledge of His will for us and the power to carry that out. 12. Having had a spiritual awakening as the result of these steps, we tried to carry this message to alcoholics and to practice these principles in all our affairs.

  31. Behavioral Therapy

  32. Project MATCH • Subjects recruited after inpatient treatment or outpatient treatment • Randomized to MET, CBT or 12-step facilitation, over 12-week period • Little difference in outcomes by type of Treatment • Aftercare after inpatient stay: 12-month continuous abstinence 35%, 40% relapsed to 3 consecutive heavy drinking days • Outpatients, 19% abstained, and 46% relapsed Project MATCH Research Group. J Stud Alcohol 1997;58:7-29

  33. Pharmacotherapy

  34. Pharmacologic Therapies for Alcohol Prevention Relapse * Drug has a Food and Drug Administration-approved indication for this use in the US O’Connor P, et al. NEJM 1998;338;9;592-602

  35. Medications for Treatment of Alcohol Dependence to Prevent Relapse Saitz R NEJM 2005;352;6;596-607

  36. Disulfiram • Multicenter RCT, 12-month F/u of N=605 • DS 250mg, 1 mg, or none • No difference in abstinence • More abstinence in those adherent to DS (43% vs. 8%,p<0.001) • Fewer drinking days in the 162 assigned to DS, adhered, and completed F/u, compared to other groups (p=0.05) Fuller RK JAMA 1986;256:1449

  37. Disulfiram • Daily or just prior to risky situation • Duration of action: 4-7 days, up to 14 • Monitor LFTS (2 wks, 3,6 Mo, 1yr), avoid alcohol in OTC meds, interacts with warfarin, INH and anticonvulsants • Contraindications • alcohol within 24 hours • Elderly, pregnancy, varices, confusion, seizures, heart disease, anti-HTN therapy, (ie. anti-adrenergics

  38. Medications for Treatment of Alcohol Dependence to Prevent Relapse Saitz R NEJM 2005;352;6;596-607

  39. Naltrexone • A meta-analysis showed that in RCTs of a short duration (< 3 months) • decreased the risk of a return to heavy drinking from 48% to 37% • Decreased drinking days by 4.5% • Proportion of patients who were abstinent was higher with naltrexone than placebo (35% vs. 30%); borderline significance Carmen B et al. Addiction 2004:99:811-28

  40. Naltrexone • Can be prescribed in the context of psychosocial treatments for those with alcohol dependence, not drinking. Last drink 5-30 days ago, LFTs < 3x normal, no opiates • Less drinking, less relapse • 12.5 mg →25mg →50mg over first few days • Med Alert bracelet, stop 3 days pre-op • Monitor LFTs, drinking and SEs monthly • ? Duration of treatment

  41. Back to Our Patient • Treatment of ARS • Brief Intervention: Goal is to link with specialized treatment center for initial detoxification • Referral to primary care • Long term treatment through behavioral and/or pharmacotherapy

  42. Thanks • Richard Saitz MD, MPH • Niels Rathlev, MD Boston University School of Medicine

More Related